🇺🇸 Sodium Polystyrene Sulfonate Oral Suspension [SPS] in United States

FDA authorised Sodium Polystyrene Sulfonate Oral Suspension [SPS] on 5 June 1958

Marketing authorisations

FDA — authorised 5 June 1958

  • Application: NDA011287
  • Marketing authorisation holder: CONCORDIA
  • Local brand name: KAYEXALATE
  • Indication: POWDER — ORAL, RECTAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Sodium Polystyrene Sulfonate Oral Suspension [SPS] in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Sodium Polystyrene Sulfonate Oral Suspension [SPS] approved in United States?

Yes. FDA authorised it on 5 June 1958; FDA has authorised it.

Who is the marketing authorisation holder for Sodium Polystyrene Sulfonate Oral Suspension [SPS] in United States?

CONCORDIA holds the US marketing authorisation.